Clinical Trial Update: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase II study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumors
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Carcinoid Tumors, Pancreatic NET | Phase 2 | Status: COMPLETED | Results posted: 2019-10-02